Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 10/20 | 0.64 |
| ▸ | MECP2 | P51608 | 1/20 | 0.56 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21795694 | 0.86 | NOTUM (0.75) | NOTUMALDH1A1HPGDMAPK1KDM4E | |
| SCHEMBL11232897 | 0.79 | NOTUM (0.74) | NOTUMALDH1A1HPGDMAPK1KDM4E | |
| SCHEMBL859977 | 0.78 | NOTUM (0.64) | NOTUMALDH1A1HPGDMAPK1KDM4E | |
| SCHEMBL3794714 | 0.78 | NOTUM (0.64) | NOTUMALDH1A1HPGDMAPK1KDM4E | |
| SCHEMBL1016310 | 0.78 | NOTUM (0.64) | NOTUMALDH1A1HPGDMAPK1KDM4E | |
| SCHEMBL23451501 | 0.78 | NOTUM (1.00) | NOTUMALDH1A1HPGDMAPK1KDM4E | |
| SCHEMBL31291162 | 0.78 | NOTUM (0.64) | NOTUMALDH1A1HPGDMAPK1KDM4E | |
| SCHEMBL21776860 | 0.78 | NOTUM (1.00) | NOTUMALDH1A1HPGDMAPK1KDM4E | |
| SCHEMBL3809272 | 0.78 | NOTUM (0.64) | NOTUMALDH1A1HPGDMAPK1KDM4E | |
| SCHEMBL11252964 | 0.77 | NOTUM (0.43) | NOTUMMECP2MAP4K4ALDH1A1TLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12116358-B2 | Substituted indoles and methods of use thereof | Epizyme, Inc. (US) | 2024-10-15 | — | — | US | disclosed |
| WO-2023101326-A1 | NOVEL COMPOUND AS AUTOTAXIN INHIBITOR AND USE THEREOF | 주식회사 넥스트젠바이오사이언스 | 2023-06-08 | — | — | WO | disclosed |
| US-20230075198-A1 | SUBSTITUTED INDOLES AND METHODS OF USE THEREOF | Epizyme, Inc. | 2023-03-09 | — | — | US | disclosed |
| WO-2023022497-A1 | SOS1 INHIBITOR AND USE THEREOF | 주식회사 카나프테라퓨틱스 | 2023-02-23 | — | — | WO | disclosed |
| CN-114829496-A | Composition, curable composition, and cured product | 大金工业株式会社 | 2022-07-29 | — | — | CN | disclosed |
| US-11345676-B2 | Apoptosis signal-regulating kinase 1 (ASK 1) inhibitor compounds | PHARMAKEA, INC. (US) | 2022-05-31 | — | — | US | disclosed |
| CN-113784999-A | Fluorine-containing epoxy resin for electrical material and method for producing same | 大金工业株式会社 | 2021-12-10 | — | — | CN | disclosed |
| EP-3858824-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | Gilead Sciences, Inc. (US) | 2021-08-04 | — | — | EP | disclosed |
| EP-3858824-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | Gilead Sciences, Inc. (US) | 2021-08-04 | — | — | EP | disclosed |
| EP-3837240-A1 | SUBSTITUTED INDOLES AND METHODS OF USE THEREOF | Epizyme, Inc. (US) | 2021-06-23 | — | — | EP | disclosed |
| US-20130012521-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2013-01-10 | — | — | US | disclosed |
| US-20130012521-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2013-01-10 | — | — | US | disclosed |
| US-20130012521-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2013-01-10 | — | — | US | disclosed |
| EP-2454250-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | Gilead Sciences, Inc. (US) | 2012-05-23 | — | — | EP | disclosed |
| WO-2011008709-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2011-01-20 | — | — | WO | disclosed |
| WO-2011008709-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2011-01-20 | — | — | WO | disclosed |
| US-20110009410-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2011-01-13 | — | — | US | disclosed |
| US-20110009410-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2011-01-13 | — | — | US | disclosed |
| US-20110009410-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2011-01-13 | — | — | US | disclosed |
| WO-2008103351-A2 | HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS | SCHERING CORPORATION (US) | 2008-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12116358-B2 | Substituted indoles and methods of use thereof | CCNE1, CCNE2, FOXM1 | NOTUM 2798/4885MECP2 4728/4885MAP4K4 3484/4885 |
| US-20110009410-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | BAX, CASP1, AIFM1 | NOTUM 4512/4885MECP2 3851/4885MAP4K4 120/4885 |
| US-20230075198-A1 | SUBSTITUTED INDOLES AND METHODS OF USE THEREOF | FOXM1, CCNE2, CCNE1 | NOTUM 3071/4885MECP2 4556/4885MAP4K4 3576/4885 |
| US-11345676-B2 | Apoptosis signal-regulating kinase 1 (ASK 1) inhibitor compounds | BAX, BAD, BCL2 | NOTUM 3838/4885MECP2 3163/4885MAP4K4 134/4885 |
| US-20130012521-A1 | APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS | BAX, CASP1, CASP6 | NOTUM 4500/4885MECP2 3771/4885MAP4K4 115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.